Q-omics provides the consensus-scored HES6 profile across patient tissues and cancer cell-line models. HES6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HES6 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, HES6 RNA expression shows 18,723 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where HES6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HES6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HES6 survival associations across molecular data types. HES6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HES6 RNA expression–survival associations across cancer types. High HES6 expression shows unfavorable associations in UVM, ACC, SKCM, ESCA and KIRC, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HES6 RNA expression.
This table summarizes HES6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for HES6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HES6 shows higher tumor expression in COAD, KIRP, HNSC, THCA, LIHC and STAD. The COAD box plot shows higher HES6 RNA expression in tumor versus normal tissue (log2 FC = +2.200, t-test p < 0.001).
This table shows molecular features associated with HES6 in patient tissues and cancer cell lines. In patient samples, HES6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HES6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
